<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898040</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000495284</org_study_id>
    <secondary_id>ECOG-E3L06T1</secondary_id>
    <nct_id>NCT00898040</nct_id>
  </id_info>
  <brief_title>Study of DNA Samples From Patients With Multiple Myeloma</brief_title>
  <official_title>Proposal for Combining ECOG Myeloma Trial SNP Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help&#xD;
      doctors learn more about changes that may occur in DNA and identify biomarkers related to&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether there is an increased frequency of 1 or more polymorphic alleles that&#xD;
           are associated with clinical endpoints using custom myeloma single nucleotide&#xD;
           polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple&#xD;
           myeloma.&#xD;
&#xD;
        -  Determine SNPs associated with toxicities caused, not by variations in tumor cell&#xD;
           genetics, but by individual genetic variations affecting drug activation, distribution,&#xD;
           metabolism, and export (ADME).&#xD;
&#xD;
        -  Determine SNPs associated with response, influenced by the same ADME.&#xD;
&#xD;
        -  Determine SNPs associated with bone disease (as a variable) among patients with multiple&#xD;
           myeloma.&#xD;
&#xD;
        -  Determine SNPs associated with epidemiology (i.e., risk factors for the development of&#xD;
           multiple myeloma).&#xD;
&#xD;
      OUTLINE: This is a retrospective, multicenter study.&#xD;
&#xD;
      Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to&#xD;
      assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and&#xD;
      response.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2006</start_date>
  <completion_date type="Actual">January 1, 2007</completion_date>
  <primary_completion_date type="Actual">January 1, 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Increased frequency of â‰¥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SNPs associated with toxicities caused by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SNPs associated with response</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SNPs associated with bone disease</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">600</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
          -  DNA samples banked from other ECOG studies (and other clinical trial groups [e.g.,&#xD;
             SWOG and MRC])&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Van Ness</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

